Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature

Cancers

Massimo Dominici¹  Chrystel Isca¹  Federica Caggia¹  Angela Toss¹  Claudia Piombino¹  Monica Barbolini¹  Federico Piacentini¹  Michela Maur²  Claudia Omarini²  Luca Moscetti²  Valentina Masciale³  Ilenia Mastrolia³ 

[1] Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, 41124 Modena, Italy;Division of Medical Oncology, Department of Oncology-Hematology, University Hospital of Modena, 41124 Modena, Italy;Laboratory of Cellular Therapy, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy;

关键词: exosome;    miRNA;    extracellular vesicles;    HER2 positive breast cancer;    early stage breast cancer;    neoadjuvant chemotherapy;   

DOI  :  10.3390/cancers13194894

来源: DOAJ

【 摘 要 】

MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor suppressors. Deregulated miRNA expression has been detected in human cancers, including breast cancer (BC). Considering their important roles in tumorigenesis, miRNAs have been investigated as potential prognostic and diagnostic biomarkers. Neoadjuvant setting is an optimal model to investigate in vivo the mechanism of treatment resistance. In the management of human epidermal growth factor receptor-2 (HER2)-positive early BC, the anti-HER2-targeted therapies have drastically changed the survival outcomes. Despite this, growing drug resistance due to the pressure of therapy is relatively frequent. In the present review, we focused on the main miRNAs involved in HER2-positive BC tumorigenesis and discussed the recent evidence on their predictive and prognostic value.

【 授权许可】

Unknown